Complex Regional Pain Syndrome (CRPS) Market Size, Share, Growth – By Disease Type, By Treatment, By Route of Administration, By End Use – Growth Forecast, 2024 – 2032

Complex Regional Pain Syndrome Market Size

The global complex regional pain syndrome market size was valued at USD 109 million in 2023 and is estimated to grow at a CAGR of over 2.4% from 2024 to 2032. The CRPS is on the rise due to the increase in the number of chronic pain cases, progress in the methods of diagnosis, as well as enhanced treatment delivery systems.
 

The analysis provided by Centers for Disease Control and Prevention (CDC), as of 2021, estimates about 20.9% of Americans in the U.S. have complain of chronic pain; this indeed shows a grave requirement for exclusive pain management mechanisms. Taking into account the estimates provided by the National Institutes of Health (NIH), CRPS is a severe condition which usually tends to develop after an injury or a surgery which alone affects almost 26.2 individuals out of 100,000 on an annual basis, and that which also serves as an indicator for CRPS chronic pain.

Additionally, the growth of diagnosing technology aids in the early detection of the disease, and even assists in quick intervention leading for the desired outcomes. New and advanced pharmacological treatments alongside non-invasive diagnostic imaging is becoming a norm, leading to an increased effectiveness in treatments for different patients.
 

The CRPS market includes a variety of products such as pharmaceuticals, diagnostic devices, medical equipment, and physical rehabilitation therapies. These services aim to diagnose, manage, and treat people suffering with chronic neuropathic pain, most commonly caused due to trauma, surgery, or injury. In other words, the market offers an array of services and drugs focused on alleviating pain and improving the overall living standard of the given individual.
 

Complex Regional Pain Syndrome Market Trends

Surgical and traumatic injuries, more often than not, lead to the growing prevalence of complex regional pain syndrome, an affliction that makes the market to expand.
 

• As CRPS becomes easier to diagnose, the range of patients needing effective treatment will increase, leading to a growth in the market itself. The recovery rates after a surgery are slow, leading to CRPS.
   
• The increasing elderly population who tend to undergo far more surgeries, coupled with slower recovery times, tend to amplify the problem drastically. Due to these increasing numbers, there arises a rapid growth for a more efficient, pain management solution.
   
• Factors such as neurostimulation devices, physical therapies, and even Pharmaceuticals have led to a stupendous shift.
   

Complex Regional Pain Syndrome Market Analysis

Based on disease type, the market is segmented into CRPS I, CRPS II, and CRPS-NOS. The CRPS I segment dominated the market with USD 91.2 million in 2023.
 

• CRPS Type I segment of the market has the former accounting for 90 % cases. This type is also known as Reflex Sympathetic Dystrophy (RSD) as it occurs because of injury or a disease not affecting the injured arm’s nerves.
   
• Thanks to the abilities of the doctor, the condition has been recognized and further emphasized which has inevitably led to increased demand for appropriate treatment and hence market growth. Moreover, improving diagnostic tools and active studies on pain management and patient’s welfare are likely to stimulate the market during the projected period.
   

Based on treatment, the complex regional pain syndrome market is divided into medication and therapy. The medication segment accounted for a significant market share of 66.1% in 2023.
 

• As per the National Institute of Neurological Disorders and Stroke (NINDS), there are 200,000 new cases of CRPS reported every year in the U.S. and most of them require a multidimensional approach as a result of the pain that they experience because of CRPS.
   
• The current therapeutic regimens for such patients have a long way to go before achieving significance. However, these neural interventions have already shown great promise in patients willing to go for amelioration for their end stage pain conditions. This has the potential of bridging the worrying gap in CRPS patients while we await effective therapeutics.
   

Based on route of administration, the complex regional pain syndrome market is divided into oral, injectable, and other routes of administration. The oral segment dominated the market with USD 63.8 million in 2023.
 

• The oral route of administration can be viewed as an important category in the CRPS industry as it enables managing chronic pain and inflammation in a simple non-invasive manner.
   
• NSAIDS, anticonvulsants and antidepressants are given to CRPS patients to decrease pain and reduce the neuropathic symptoms in order to enhance their performance.
   

Based on end use, the complex regional pain syndrome market is divided into hospitals, clinics, and other end users. The hospitals segment dominated the market in 2023 and expected to reach 77.7 million within the forecast period.
 

• In CRPS, hospitals serve as significant end-users by offering multidisciplinary relief from severe pain conditions. They offer specific care such as physical remediation, nervous blockage and administering medications through the veins to alleviate pain in patients suffering from CRPS, when oral medications prove insufficient.
   
• Hospitals help avoid delays in the development of individualized mortar devices for managing pain, as well as the management of pain itself, which crucially improves patient outcomes. Furthermore, other roles of hospitals include the offering of new, improved treatment possibilities, clinical trial studies and the modification of existing drugs which all aid to the management of CRPS pain and enhance the therapeutics.
   

U.S. CRPS market is expected to grow at 2.3% CAGR, to reach USD 49.8 million by the end of 2032.
 

• The strong presence of CRPS patients and demand of services has led to the growth of the U.S. market and this is aided by the strong healthcare facility available. Such activities as increased occurrence of CRPS is as a consequence of an upsurge in the number of operations and cases of trauma. Great effort is also made in furthering the development of CRPS targeted therapies such as neuro stimulation and other medications as there is increased funding in the area.
   
• Moreover, the government of the U.S. of America assists this market by promoting the initiatives that aim at bettering the practices for pain management and curbing opioid abuse which in turn helps in expanding the treatment options for CRPS.
   

The Germany market is experiencing robust growth in the European complex regional pain syndrome market.  
 

• With the increasing aged population that is more prone to CRPS, there is rising demand for the more advanced technology that Germany offers in this market of CRPS which is further re-enforced by the demand for cutting edge technology and medical facilities.
   
• Innovation in neurostimulation devices along with other research in pain therapy is being promoted in Germany, with support from the government for both the private and public sectors which will help transform the market. CRPS being one of the targeted areas, awareness programs aided by pain management centers are being established.
   

The Asia Pacific complex regional pain syndrome market is witnessing substantial growth of 2.7% CAGR during the analysis period.
 

• There is rapid expansion of China’s market due to the increased spending on healthcare, rising number of surgeries and better diagnosing of chronic pain conditions.
   
• Rural areas particularly have very low supply for specialized pain management so the treatment for CRPS that includes neurostimulation and the pharmaceutical options for pain management does not remain a viable option but as there is greater awareness regarding CRPS and its treatment options in urban areas, the demand for it is rapidly increasing.
   

The Brazil market is experiencing robust growth in Latin America.
 

• Due to the growing injury rates along with the improving surgeries and healthcare access, there has been a growth in the awareness regarding the alternate therapies for pain management which is expected to fuel Brazil’s market further.
   

The Saudi Arabia complex regional pain syndrome market is witnessing substantial growth during the analysis period.
 

• With the enhancement of the healthcare system in the country and addressing the awareness factor, the market in Saudi Arabia has started to emerge, and jointly with the increasing population of elderly there would be a lot of room for pain alleviation techniques needed for civilizational diseases such as CRPS.
   
• The Vision 2030 plan makes the Saudi environment conducive for new ideas and innovations in the area of healthcare for chronic pain and development of the required medicines and equipment as a means to strengthen the economy of Saudi Arabia. This is highly possible as Vison2030 is a government initiative.
   

Complex Regional Pain Syndrome Market Share

The services that focus on the medical care offered by hospitals and clinics in CRPS are progressing at a fast pace considering the accuracy of the treatment and pain management systems respectively. This is because CRPS is a relatively less explored market but has the potential of delivering high ROIs so there are leading brands that sell or aim to sell refined analgesics and neurostimulation devices designed specifically for chronic pain in the CRPS arena.
 

As the competition in the healthcare sector is fierce, it is necessary to have acquired or established partnerships, innovative high-tech solutions or mergers in order to expand in this area. Also, consistent R&D and investments in the neuromodulation area facilitate capturing new segments of the treatment landscape, being able to meet the needs of the patients. The wider market of precision pain therapies is growing and the maintaining of influence in this market is key.
 

Complex Regional Pain Syndrome Market Companies

Major players operating in the complex regional pain syndrome industry are:

• Abbott Laboratories
• AbbVie
• Averitas Pharma
• Boston Scientific
• Collegium Pharmaceutical
• Eli Lilly and Company
• Mallinckrodt Pharmaceuticals
• Medtronic
• Nevro
• Pfizer
• Sandoz
• Teva Pharmaceutical
   

USPs for Key Players:

• Medtronic pioneers in neuromodulation therapies, offering advanced spinal cord stimulation (SCS) systems for long-term CRPS pain management.
   
• Pfizer enables a strong portfolio of analgesics and neuropathic pain medications, ensuring effective pharmacological treatment options for CRPS patients.
   
• Boston Scientific specializes in innovative pain management devices, including high-frequency and rechargeable SCS systems for personalized CRPS therapy.
   

Complex Regional Pain Syndrome Industry News

• In April 2024, Medtronic received FDA approval for its Inceptiv closed-loop spinal cord stimulator, designed to offer personalized pain relief by adjusting stimulation in real-time. This advancement aims to improve outcomes for patients with CRPS and chronic pain.
   
• In January 2024, Medtronic received FDA approval for its Percept RC neurostimulator, featuring exclusive BrainSense technology. This device monitors brain signals and makes stimulation in real-time, providing enhanced treatment options for patients managing CRPS and other chronic pain conditions.
   

The complex regional pain syndrome market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Disease Type

• CRPS I
• CRPS II
• CRPS-NOS

Market, By Treatment

• Medication
  • Analgesics
  • Antidepressants
  • Corticosteroids
  • Opioids
  • Other medications
• Therapy
  • Physical therapy
  • Intrathecal drug pump
  • Spinal cord stimulation
  • Surgical sympathectomy
  • Other therapies

Market, By Route of Administration 

• Oral
• Injectable
• Other routes of administration

Market, By End Use

• Hospitals
• Clinics
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE